Secondary prevention with folic acid: Effects on clinical outcomes

Journal of the American College of Cardiology

Volumn 41, Issue 12, 2003, Pages 2105-2113

  Liem, Anho ^a   Reynierse Buitenwerf, Giny H ^a   Zwinderman, Aeilko H ^b   Jukema, J Wouter ^c   Van Veldhuisen, Dirk J ^d  

^a Oosterschelde Ziekenhuizen ^*  (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CREATININE; CYANOCOBALAMIN; FIBRINOGEN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DRUG EFFECT; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SECONDARY PREVENTION; SURVIVAL TIME; VASCULAR ENDOTHELIUM;

EID: 0038648465     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00485-6     Document Type: Article

References (24)

1. Anderson JL, Muhlestein JB, Horne BD, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000;102:1227-32.
2. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
3. Knekt P, Reunanen A, Alfthan G, et al. Hyperhomocysteinemia: a risk factor or a consequence of coronary heart disease? Arch Intern Med 2001;161:2628-9.
4. Schnyder G, Flammer Y, Roffi M, et al. Plasma homocysteine levels and late outcome after coronary angioplasty. J Am Coll Cardiol 2002;40:1769-76.
5. Boushcy CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
6. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.
7. Verhaar MC, Wever RM, Kastelein JJ, et al. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial. Circulation 1999;100:335-8.
8. Chambers JC, Ueland PM, Obeid OA, et al. Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000;102:2479-83.
9. den Heijer M, Brouwer IA, Bos GM, et al. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998;18:356-61.
10. Doshi SN, McDowell IF, Moat SJ, et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 2002;105:22-6.
11. Schnyder G, Roffi M, Pin R. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001;345:1593-600.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
13. Christen WG, Ajani UA, Glynn RJ, et al. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med 2000;160:422-34.
14. Ueland PM, Refsum H, Beresford SA, et al. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000;72:324-32.
15. Wald DS, Law M, Mooris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202-9.
16. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. A meta-analysis. JAMA 2002;288:2015-22.
17. Baker F, Picton D, Blackwood S, et al. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial (abstr). Circulation 2002;106 Suppl II:2-741.
18. Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-8.
19. Quinlivan EP, McPartlin J, McNulty H, et al. Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. Lancet 2002;359:227-8.
20. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279:1477-82.
21. Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-55.
22. Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-41.
23. Ernst E. Fibrinogen: an important risk factor for atherothrombotic disease. Ann Med 1994;26:15-22.
24. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.